Ocular Therapeutix (OCUL) Current Leases (2019 - 2026)

Ocular Therapeutix has reported Current Leases for 8 years, with the latest figure at $3.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 47.03% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (up 47.03% YoY), and the FY2025 full-year result was $2.8 million, up 45.73% from the prior year.
• Current Leases for Q1 2026 stood at $3.2 million, up from $2.8 million in the prior quarter.
• The five-year high for Current Leases was $3.2 million in Q1 2026, with the low at $1.5 million in Q1 2024.
• Average Current Leases over 5 years is $2.0 million, with a median of $1.8 million recorded in 2022.
• Year-over-year, Current Leases retreated 15.18% in 2024 and surged 60.86% in 2025.
• Tracing OCUL's Current Leases over 5 years: stood at $1.6 million in 2022, then dropped by 0.81% to $1.6 million in 2023, then gained by 21.88% to $1.9 million in 2024, then jumped by 45.73% to $2.8 million in 2025, then climbed by 12.53% to $3.2 million in 2026.
• The last three Current Leases figures came in at $3.2 million (Q1 2026), $2.8 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.

Peer Comparison